Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.

PFE offers a 6.73% dividend yield and growth potential, driven by strategic acquisitions, R&D, and discounted valuations.

Pfizer reported fourth-quarter 2024 adjusted ... driven by strong contributions from Padcev, Xtandi, Lorbrena and Braftovi/Mektovi. In Primary Care, alliance revenues and direct sales from Bristol ...

Pfizer Inc. (NYSE:PFE ... with potential to triple its patient reach. As of Q4 2024, Braftovi/Mektovi saw a 27% year-over-year global growth, and recent data showed survival improvements in ...

First-line, targeted therapy for colorectal cancer Pfizer's BRAF inhibitor Braftovi (encorafenib) has been given accelerated approval by the FDA as first-line therapy for BRAF V600E-mutated ...